Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers
domain containing protein tyrosine phosphatase-2 (SHP2) is a highly attractive therapeutic target for treating Kirsten rat sarcoma viral oncogene (KRAS) mutant cancers. In this work, a series of guanidine-based SHP2allostericinhibitors were discovered via virtual screening and rational structural optimization. Notably, lead compound 23 with potent SHP2 inhibitory activity (IC50 = 17.7 nM) effectively
FERRIS, JAMES P.;HUANG, CHUN-HSIEN;HAGAN, WILLIAM J. (JR), NUCLEOSIDES AND NUCLEOTIDES, 8,(1989) N, C. 407-414
作者:FERRIS, JAMES P.、HUANG, CHUN-HSIEN、HAGAN, WILLIAM J. (JR)
DOI:——
日期:——
Direct Synthesis of Guanidines Using Di(imidazole-1-yl)methanimine
作者:Yong-Qian Wu、Sean K. Hamilton、Douglas E. Wilkinson、Gregory S. Hamilton
DOI:10.1021/jo0202381
日期:2002.10.1
A direct synthetic approach to guanidine compounds is reported here usingdi(imidazole-1-yl)methanimine and di(imidazole-1-yl)cyanomethanimine as guanylating reagents.
The synthesis of 2-amino-4(3H)-quinazolinones and related heterocycles via a mild electrocyclization of aryl guanidines
作者:Zachary S. Sales、Neelakandha S. Mani、Brett D. Allison
DOI:10.1016/j.tetlet.2018.03.034
日期:2018.4
A new method for the preparation of 2-amino-4(3H)-quinazolinones and similar fused heterocycles is described. Simply warming a mixture of an aryl guanidine and carbonyl diimidazole in acetonitrile results in formation of a putative N-amidinoisocyanate intermediate which undergoes a 6π-electron electrocyclic reaction with the aryl ring to generate the quinazolinone ring system. The mild conditions are